GLP-1受体激动剂通过抑制食欲而减重的机制
Mechanism of GLP-1 Receptor Agonists in Weight Loss through Appetite Suppression
DOI: 10.12677/acm.2026.1641386, PDF,   
作者: 姚张婉儿*, 葛 倩#：重庆医科大学附属第一医院内分泌内科，重庆
关键词: 肥胖；GLP-1受体激动剂；食欲抑制；Obesity； GLP-1 Receptor Agonists； Appetite Suppression
摘要: 目的：本文综述了GLP-1受体激动剂食欲抑制的机制，对食欲影响的评估方法。方法：首先，本文对GLP-1受体激动剂的发展作出了简述，对比了一般的食欲调节和GLP-1受体激动剂食欲调节的相同及不同机制。重点阐述了食欲量化评估部分，将各类评估方法的优缺点与GLP-1具体的作用机制相结合，并分析了关键的神经影像学证据。结果：本文发现以GLP-1受体为药物作用靶点的减重新药层出不穷，但食欲抑制的机制尚不明确；现有研究在食欲量化评估上存在方法学短板，缺乏将主观感受、客观摄入行为与神经影像数据的多维整合。结论：本文旨在为药物减重的研究人员及减重科的临床医生提供一些参考，特别是通过提出“中枢各脑区作用的整合与协同机制”假说，为未来研究方向及个体化用药策略提供启发。
Abstract: Objective: This article reviews the mechanisms by which GLP-1 receptor agonists suppress appetite and summarizes the methods for evaluating appetite. Methods: Firstly, this article provides a brief overview of the development of GLP-1 receptor agonists. It compares the similarities and differences between general appetite regulation mechanisms and those mediated by GLP-1 receptor agonists. Crucially, it elaborates on appetite quantification assessments, integrating the strengths and limitations of various evaluation methods with the specific mechanisms of GLP-1. Results: The review finds that while new weight-loss drugs targeting the GLP-1 receptor are emerging constantly, the appetite suppression mechanisms remain unclear. Furthermore, existing studies exhibit methodological shortcomings in appetite quantification, lacking a multidimensional integration of subjective sensations, objective intake behaviors, and neuroimaging data. Conclusion: This article aims to provide a reference for researchers in pharmacological weight loss and clinicians in weight management departments. Specifically, by proposing the hypothesis of an “integrative and synergistic mechanism across central brain regions”, it offers insights for future research directions and strategies for individualized medication.
文章引用：姚张婉儿, 葛倩. GLP-1受体激动剂通过抑制食欲而减重的机制[J]. 临床医学进展, 2026, 16(4): 1514-1523. https://doi.org/10.12677/acm.2026.1641386

参考文献

[1] World Health Organization (2024) Obesity and Overweight.
https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
[2] Afshin, A., Forouzanfar, M.H., Reitsma, M.B., et al. (2017) Health Effects of Overweight and Obesity in 195 Countries over 25 Years. New England Journal of Medicine, 377, 13-27. [Google Scholar] [CrossRef] [PubMed]
[3] 李一君. 我国肥胖症及其并发症评估的挑战与机遇——基于大样本流行病学研究的思考[J]. 中华内科杂志, 2023, 62(12): 1361-1366.
[4] Camilleri, M. and Acosta, A. (2018) Combination Therapies for Obesity. Metabolic Syndrome and Related Disorders, 16, 390-394. [Google Scholar] [CrossRef] [PubMed]
[5] Chakhtoura, M., Haber, R., Ghezzawi, M., Rhayem, C., Tcheroyan, R. and Mantzoros, C.S. (2023) Pharmacotherapy of Obesity: An Update on the Available Medications and Drugs under Investigation. eClinicalMedicine, 58, Article 101882. [Google Scholar] [CrossRef] [PubMed]
[6] 中华医学会内分泌学分会. 肥胖患者的长期体重管理及药物临床应用指南(2024版) [J]. 中华内分泌代谢杂志, 2024, 40(7): 545-564.
[7] Ruseva, A., Michalak, W., Zhao, Z., Fabricatore, A., Hartaigh, B.Ó. and Umashanker, D. (2024) Semaglutide 2.4 mg Clinical Outcomes in Patients with Obesity or Overweight in a Real‐World Setting: A 6‐Month Retrospective Study in the United States (Scope). Obesity Science & Practice, 10, e737. [Google Scholar] [CrossRef] [PubMed]
[8] Wilding, J.P.H., Batterham, R.L., Calanna, S., Davies, M., Van Gaal, L.F., Lingvay, I., et al. (2021) Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384, 989-1002. [Google Scholar] [CrossRef] [PubMed]
[9] Ghusn, W., De la Rosa, A., Sacoto, D., Cifuentes, L., Campos, A., Feris, F., et al. (2022) Weight Loss Outcomes Associated with Semaglutide Treatment for Patients with Overweight or Obesity. JAMA Network Open, 5, e2231982. [Google Scholar] [CrossRef] [PubMed]
[10] 韩美芬, 赵家军. 司美格鲁肽在治疗肥胖症中的作用机制及临床应用进展[J]. 中国新药杂志, 2022, 31(9): 859-864.
[11] Drucker, D.J. (2022) GLP-1 Physiology Informs the Pharmacotherapy of Obesity. Molecular Metabolism, 57, Article 101351. [Google Scholar] [CrossRef] [PubMed]
[12] Drucker, D.J., Philippe, J., Mojsov, S., Chick, W.L. and Habener, J.F. (1987) Glucagon-Like Peptide I Stimulates Insulin Gene Expression and Increases Cyclic AMP Levels in a Rat Islet Cell Line. Proceedings of the National Academy of Sciences, 84, 3434-3438. [Google Scholar] [CrossRef] [PubMed]
[13] Mojsov, S., Weir, G.C. and Habener, J.F. (1987) Insulinotropin: Glucagon-Like Peptide I (7-37) Co-Encoded in the Glucagon Gene Is a Potent Stimulator of Insulin Release in the Perfused Rat Pancreas. Journal of Clinical Investigation, 79, 616-619. [Google Scholar] [CrossRef] [PubMed]
[14] Holst, J.J., Ørskov, C., Vagn Nielsen, O. and Schwartz, T.W. (1987) Truncated Glucagon‐Like Peptide I, an Insulin‐releasing Hormone from the Distal Gut. FEBS Letters, 211, 169-174. [Google Scholar] [CrossRef] [PubMed]
[15] Nathan, D.M., Schreiber, E., Fogel, H., Mojsov, S. and Habener, J.F. (1992) Insulinotropic Action of Glucagonlike Peptide-I-(7-37) in Diabetic and Nondiabetic Subjects. Diabetes Care, 15, 270-276. [Google Scholar] [CrossRef] [PubMed]
[16] Kolterman, O.G., Kim, D.D., Shen, L., Ruggles, J.A., Nielsen, L.L., Fineman, M.S., et al. (2005) Pharmacokinetics, Pharmacodynamics, and Safety of Exenatide in Patients with Type 2 Diabetes Mellitus. American Journal of Health-System Pharmacy, 62, 173-181. [Google Scholar] [CrossRef] [PubMed]
[17] Finan, B., Clemmensen, C. and Müller, T.D. (2015) Emerging Opportunities for the Treatment of Metabolic Diseases: Glucagon-Like Peptide-1 Based Multi-agonists. Molecular and Cellular Endocrinology, 418, 42-54. [Google Scholar] [CrossRef] [PubMed]
[18] Jastreboff, A.M., Aronne, L.J., Ahmad, N.N., Wharton, S., Connery, L., Alves, B., et al. (2022) Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387, 205-216. [Google Scholar] [CrossRef] [PubMed]
[19] Garvey, W.T., Frias, J.P., Jastreboff, A.M., le Roux, C.W., Sattar, N., Aizenberg, D., et al. (2023) Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2): A Double-Blind, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial. The Lancet, 402, 613-626. [Google Scholar] [CrossRef] [PubMed]
[20] Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., et al. (2015) A Randomized, Controlled Trial of 3.0 Mg of Liraglutide in Weight Management. New England Journal of Medicine, 373, 11-22. [Google Scholar] [CrossRef] [PubMed]
[21] Ng, C.D., Divino, V., Wang, J., Toliver, J.C. and Buss, M. (2025) Real-World Weight Loss Observed with Semaglutide and Tirzepatide in Patients with Overweight or Obesity and without Type 2 Diabetes (Shape). Advances in Therapy, 42, 5468-5480. [Google Scholar] [CrossRef] 
[22] Courrèges, J.‐., Vilsbøll, T., Zdravkovic, M., Le‐Thi, T., Krarup, T., Schmitz, O., et al. (2008) Beneficial Effects of Once‐Daily Liraglutide, a Human Glucagon‐Like Peptide‐1 Analogue, on Cardiovascular Risk Biomarkers in Patients with Type 2 Diabetes. Diabetic Medicine, 25, 1129-1131. [Google Scholar] [CrossRef] [PubMed]
[23] Noyan-Ashraf, M.H., Momen, M.A., Ban, K., Sadi, A., Zhou, Y., Riazi, A.M., et al. (2009) GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes after Experimental Myocardial Infarction in Mice. Diabetes, 58, 975-983. [Google Scholar] [CrossRef] [PubMed]
[24] Drucker, D.J. (2018) The Ascending GLP-1 Road from Clinical Safety to Reduction of Cardiovascular Complications. Diabetes, 67, 1710-1719. [Google Scholar] [CrossRef] [PubMed]
[25] 陈天. 胰高血糖素样肽-1受体激动剂在非酒精性脂肪肝病患者中应用的荟萃分析[D]: [硕士学位论文]. 太原: 山西医科大学, 2021.
[26] Newsome, P.N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., et al. (2021) A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. New England Journal of Medicine, 384, 1113-1124. [Google Scholar] [CrossRef] [PubMed]
[27] Hjerpsted, J.B., Flint, A., Brooks, A., Axelsen, M.B., Kvist, T. and Blundell, J. (2017) Semaglutide Improves Postprandial Glucose and Lipid Metabolism, and Delays First‐Hour Gastric Emptying in Subjects with Obesity. Diabetes, Obesity and Metabolism, 20, 610-619. [Google Scholar] [CrossRef] [PubMed]
[28] Yang, R., Zhang, L., Guo, J., Wang, N., Zhang, Q., Qi, Z., et al. (2025) Glucagon-Like Peptide-1 Receptor Agonists for Obstructive Sleep Apnea in Patients with Obesity and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis. Journal of Translational Medicine, 23, Article 389. [Google Scholar] [CrossRef] [PubMed]
[29] Egecioglu, E., Steensland, P., Fredriksson, I., Feltmann, K., Engel, J.A. and Jerlhag, E. (2013) The Glucagon-Like Peptide 1 Analogue Exendin-4 Attenuates Alcohol Mediated Behaviors in Rodents. Psychoneuroendocrinology, 38, 1259-1270. [Google Scholar] [CrossRef] [PubMed]
[30] Femminella, G.D., Frangou, E., Love, S.B., Busza, G., Holmes, C., Ritchie, C., et al. (2019) Evaluating the Effects of the Novel GLP-1 Analogue Liraglutide in Alzheimer’s Disease: Study Protocol for a Randomised Controlled Trial (ELAD Study). Trials, 20, Article 191. [Google Scholar] [CrossRef] [PubMed]
[31] Gejl, M., Brock, B., Egefjord, L., Vang, K., Rungby, J. and Gjedde, A. (2017) Blood-Brain Glucose Transfer in Alzheimer’s Disease: Effect of GLP-1 Analog Treatment. Scientific Reports, 7, Article No. 17490. [Google Scholar] [CrossRef] [PubMed]
[32] Hansen, H.H., Barkholt, P., Fabricius, K., Jelsing, J., Terwel, D., Pyke, C., et al. (2016) The GLP-1 Receptor Agonist Liraglutide Reduces Pathology-Specific Tau Phosphorylation and Improves Motor Function in a Transgenic Htaup301l Mouse Model of Tauopathy. Brain Research, 1634, 158-170. [Google Scholar] [CrossRef] [PubMed]
[33] Ludvik, B., Giorgino, F., Jódar, E., Frias, J.P., Fernández Landó, L., Brown, K., et al. (2021) Once-Weekly Tirzepatide versus Once-Daily Insulin Degludec as Add-On to Metformin with or without SGLT2 Inhibitors in Patients with Type 2 Diabetes (SURPASS-3): A Randomised, Open-Label, Parallel-Group, Phase 3 Trial. The Lancet, 398, 583-598. [Google Scholar] [CrossRef] [PubMed]
[34] 王媛, 郭晓蕙. 治疗糖尿病和肥胖症的胃肠道激素类多受体激动剂研究进展[J]. 中国新药杂志, 2023, 32(6): 561-568.
[35] Melson, E., Ashraf, U., Papamargaritis, D. and Davies, M.J. (2025) What Is the Pipeline for Future Medications for Obesity? International Journal of Obesity, 49, 433-451. [Google Scholar] [CrossRef] [PubMed]
[36] Frías, J.P., Davies, M.J., Rosenstock, J., Pérez Manghi, F.C., Fernández Landó, L., Bergman, B.K., et al. (2021) Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385, 503-515. [Google Scholar] [CrossRef] [PubMed]
[37] Jastreboff, A.M., Kaplan, L.M., Frías, J.P., Wu, Q., Du, Y., Gurbuz, S., et al. (2023) Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial. New England Journal of Medicine, 389, 514-526. [Google Scholar] [CrossRef] [PubMed]
[38] Knerr, P.J., Mowery, S.A., Douros, J.D., Premdjee, B., Hjøllund, K.R., He, Y., et al. (2022) Next Generation GLP-1/GIP/Glucagon Triple Agonists Normalize Body Weight in Obese Mice. Molecular Metabolism, 63, Article 101533. [Google Scholar] [CrossRef] [PubMed]
[39] Rosenstock, J., Frias, J., Jastreboff, A.M., Du, Y., Lou, J., Gurbuz, S., et al. (2023) Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes: A Randomised, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Phase 2 Trial Conducted in the Usa. The Lancet, 402, 529-544. [Google Scholar] [CrossRef] [PubMed]
[40] Moll, H., Frey, E., Gerber, P., Geidl, B., Kaufmann, M., Braun, J., et al. (2024) GLP-1 Receptor Agonists for Weight Reduction in People Living with Obesity but without Diabetes: A Living Benefit-Harm Modelling Study. eClinicalMedicine, 73, Article 102661. [Google Scholar] [CrossRef] [PubMed]
[41] Edholm, O.G. (1977) Energy Balance in Man Studies Carried out by the Division of Human Physiology, National Institute for Medical Research. Journal of Human Nutrition, 31, 413-431.
[42] Woods, S.C. and Ramsay, D.S. (2011) Food Intake, Metabolism and Homeostasis. Physiology & Behavior, 104, 4-7. [Google Scholar] [CrossRef] [PubMed]
[43] Stensel, D. (2010) Exercise, Appetite and Appetite-Regulating Hormones: Implications for Food Intake and Weight Control. Annals of Nutrition and Metabolism, 57, 36-42. [Google Scholar] [CrossRef] [PubMed]
[44] Watts, A.G., Kanoski, S.E., Sanchez-Watts, G. and Langhans, W. (2022) The Physiological Control of Eating: Signals, Neurons, and Networks. Physiological Reviews, 102, 689-813. [Google Scholar] [CrossRef] [PubMed]
[45] Morton, G.J., Cummings, D.E., Baskin, D.G., Barsh, G.S. and Schwartz, M.W. (2006) Central Nervous System Control of Food Intake and Body Weight. Nature, 443, 289-295. [Google Scholar] [CrossRef] [PubMed]
[46] Saper, C.B., Chou, T.C. and Elmquist, J.K. (2002) The Need to Feed: Homeostatic and Hedonic Control of Eating. Neuron, 36, 199-211. [Google Scholar] [CrossRef] [PubMed]
[47] Gong, R., Xu, S., Hermundstad, A., Yu, Y. and Sternson, S.M. (2020) Hindbrain Double-Negative Feedback Mediates Palatability-Guided Food and Water Consumption. Cell, 182, 1589-1605.e22. [Google Scholar] [CrossRef] [PubMed]
[48] Zhu, C., Yao, Y., Xiong, Y., Cheng, M., Chen, J., Zhao, R., et al. (2017) Somatostatin Neurons in the Basal Forebrain Promote High-Calorie Food Intake. Cell Reports, 20, 112-123. [Google Scholar] [CrossRef] [PubMed]
[49] Burnett, C.J., Li, C., Webber, E., Tsaousidou, E., Xue, S.Y., Brüning, J.C., et al. (2016) Hunger-Driven Motivational State Competition. Neuron, 92, 187-201. [Google Scholar] [CrossRef] [PubMed]
[50] Jais, A., Paeger, L., Sotelo-Hitschfeld, T., Bremser, S., Prinzensteiner, M., Klemm, P., et al. (2020) PNOCARC Neurons Promote Hyperphagia and Obesity Upon High-Fat-Diet Feeding. Neuron, 106, 1009-1025.e10. [Google Scholar] [CrossRef] [PubMed]
[51] Rossi, M.A. and Stuber, G.D. (2018) Overlapping Brain Circuits for Homeostatic and Hedonic Feeding. Cell Metabolism, 27, 42-56. [Google Scholar] [CrossRef] [PubMed]
[52] Andermann, M.L. and Lowell, B.B. (2017) Toward a Wiring Diagram Understanding of Appetite Control. Neuron, 95, 757-778. [Google Scholar] [CrossRef] [PubMed]
[53] Tan, T.M., Field, B.C.T., McCullough, K.A., Troke, R.C., Chambers, E.S., Salem, V., et al. (2013) Coadministration of Glucagon-Like Peptide-1 during Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia. Diabetes, 62, 1131-1138. [Google Scholar] [CrossRef] [PubMed]
[54] Bagger, J.I., Holst, J.J., Hartmann, B., Andersen, B., Knop, F.K. and Vilsbøll, T. (2015) Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon + GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure. The Journal of Clinical Endocrinology & Metabolism, 100, 4541-4552. [Google Scholar] [CrossRef] [PubMed]
[55] Krieger, J., Santos da Conceição, E.P., Sanchez-Watts, G., Arnold, M., Pettersen, K.G., Mohammed, M., et al. (2018) Glucagon-like Peptide-1 Regulates Brown Adipose Tissue Thermogenesis via the Gut-Brain Axis in Rats. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 315, R708-R720. [Google Scholar] [CrossRef] [PubMed]
[56] Plamboeck, A., Veedfald, S., Deacon, C.F., Hartmann, B., Wettergren, A., Svendsen, L.B., et al. (2013) The Effect of Exogenous GLP-1 on Food Intake Is Lost in Male Truncally Vagotomized Subjects with Pyloroplasty. American Journal of Physiology-Gastrointestinal and Liver Physiology, 304, G1117-G1127. [Google Scholar] [CrossRef] [PubMed]
[57] Hayes, M.R., Bradley, L. and Grill, H.J. (2009) Endogenous Hindbrain Glucagon-Like Peptide-1 Receptor Activation Contributes to the Control of Food Intake by Mediating Gastric Satiation Signaling. Endocrinology, 150, 2654-2659. [Google Scholar] [CrossRef] [PubMed]
[58] Parkinson, J.R.C., Chaudhri, O.B., Kuo, Y., Field, B.C.T., Herlihy, A.H., Dhillo, W.S., et al. (2009) Differential Patterns of Neuronal Activation in the Brainstem and Hypothalamus Following Peripheral Injection of GLP-1, Oxyntomodulin and Lithium Chloride in Mice Detected by Manganese-Enhanced Magnetic Resonance Imaging (MEMRI). NeuroImage, 44, 1022-1031. [Google Scholar] [CrossRef] [PubMed]
[59] Turton, M.D., O’Shea, D., Gunn, I., Beak, S.A., Edwards, C.M.B., Meeran, K., et al. (1996) A Role for Glucagon-Like Peptide-1 in the Central Regulation of Feeding. Nature, 379, 69-72. [Google Scholar] [CrossRef] [PubMed]
[60] Secher, A., Jelsing, J., Baquero, A.F., Hecksher-Sørensen, J., Cowley, M.A., Dalbøge, L.S., et al. (2014) The Arcuate Nucleus Mediates GLP-1 Receptor Agonist Liraglutide-Dependent Weight Loss. Journal of Clinical Investigation, 124, 4473-4488. [Google Scholar] [CrossRef] [PubMed]
[61] Larsen, P.J., Tang-Christensen, M. and Jessop, D.S. (1997) Central Administration of Glucagon-Like Peptide-1 Activates Hypothalamic Neuroendocrine Neurons in the Rat. Endocrinology, 138, 4445-4455. [Google Scholar] [CrossRef] [PubMed]
[62] Mietlicki-Baase, E.G., Ortinski, P.I., Rupprecht, L.E., Olivos, D.R., Alhadeff, A.L., Pierce, R.C., et al. (2013) The Food Intake-Suppressive Effects of Glucagon-Like Peptide-1 Receptor Signaling in the Ventral Tegmental Area Are Mediated by AMPA/Kainate Receptors. American Journal of Physiology-Endocrinology and Metabolism, 305, E1367-E1374. [Google Scholar] [CrossRef] [PubMed]
[63] Dickson, S.L., Shirazi, R.H., Hansson, C., Bergquist, F., Nissbrandt, H. and Skibicka, K.P. (2012) The Glucagon-Like Peptide 1 (GLP-1) Analogue, Exendin-4, Decreases the Rewarding Value of Food: A New Role for Mesolimbic GLP-1 Receptors. The Journal of Neuroscience, 32, 4812-4820. [Google Scholar] [CrossRef] [PubMed]
[64] Richard, J.E., Anderberg, R.H., Göteson, A., Gribble, F.M., Reimann, F. and Skibicka, K.P. (2015) Activation of the GLP-1 Receptors in the Nucleus of the Solitary Tract Reduces Food Reward Behavior and Targets the Mesolimbic System. PLOS ONE, 10, e0119034. [Google Scholar] [CrossRef] [PubMed]
[65] Wharton, S., Batterham, R.L., Bhatta, M., Buscemi, S., Christensen, L.N., Frias, J.P., et al. (2023) Two‐Year Effect of Semaglutide 2.4 Mg on Control of Eating in Adults with Overweight/Obesity: Step 5. Obesity, 31, 703-715. [Google Scholar] [CrossRef] [PubMed]
[66] King, J.A., Thackray, A.E., Gibbons, C., Martins, C., Broom, D.R., Stensel, D.J., et al. (2025) The Mixed-Meal Tolerance Test as an Appetite Assay: Methodological and Practical Considerations. International Journal of Obesity, 49, 2168-2183. [Google Scholar] [CrossRef] [PubMed]
[67] Randle, M.W. (2020) Appetite Control and Dietary Adherence during Intermittent Energy Restriction in Naturalistic Settings Using Ecological Momentary Assessment. Master’s Thesis, University of Birmingham.
[68] Giezenaar, C., Lange, K., Hausken, T., Jones, K.L., Horowitz, M., Chapman, I., et al. (2018) Acute Effects of Substitution, and Addition, of Carbohydrates and Fat to Protein on Gastric Emptying, Blood Glucose, Gut Hormones, Appetite, and Energy Intake. Nutrients, 10, Article 1451. [Google Scholar] [CrossRef] [PubMed]
[69] van Bloemendaal, L., IJzerman, R.G., ten Kulve, J.S., Barkhof, F., Konrad, R.J., Drent, M.L., et al. (2014) GLP-1 Receptor Activation Modulates Appetite-and Reward-Related Brain Areas in Humans. Diabetes, 63, 4186-4196. [Google Scholar] [CrossRef] [PubMed]

为你推荐